Aligos Therapeutics (NASDAQ:ALGS) Stock Rating Lowered by Wall Street Zen

Aligos Therapeutics (NASDAQ:ALGS) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms have also recently commented on ALGS. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, January 21st. UBS Group began coverage on shares of Aligos Therapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $20.00 price target on the stock. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Aligos Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $35.00.

Aligos Therapeutics Price Performance

ALGS opened at $6.98 on Friday. The firm has a market capitalization of $42.95 million, a PE ratio of -0.81 and a beta of 2.67. The business’s 50-day moving average is $7.88 and its two-hundred day moving average is $9.07. Aligos Therapeutics has a 1 year low of $3.76 and a 1 year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) EPS for the quarter, beating the consensus estimate of ($2.09) by $0.18. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative return on equity of 28.16%. The business had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.27 million. As a group, sell-side analysts expect that Aligos Therapeutics will post -10.36 EPS for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of ALGS. NorthCrest Asset Manangement LLC purchased a new position in Aligos Therapeutics during the 3rd quarter worth approximately $98,000. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics in the 3rd quarter valued at $99,000. HRT Financial LP purchased a new stake in shares of Aligos Therapeutics in the 4th quarter valued at $106,000. DRW Securities LLC acquired a new stake in shares of Aligos Therapeutics in the fourth quarter worth $111,000. Finally, XTX Topco Ltd acquired a new stake in shares of Aligos Therapeutics in the second quarter worth $100,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.